We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata (“AA”).
Both the candidates met the primary endpoint of improving hair regrowth on the scalp compared to baseline over 24 weeks of treatment. Data from the study was presented at the European Academy of Dermatology and Venereology Congress, which was held in France.
The FDA granted Breakthrough Therapy designation to PF-06651600 based on these data earlier this month.
Pfizer’s stock has outperformed the industry this year so far. Pfizer’s shares have risen 18.6% compared with the industry’s increase of 6%.
Alopecia areata is an autoimmune dermatologic condition, which results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients.
Pfizer will advance PF-06651600 in phase III stage based on the data. The company is also developing PF-06651600 for rheumatoid arthritis, Crohn’s disease (“CD”) and ulcerative colitis (“UC”), and PF-06700841 for psoriasis, CD and UC.
Aclaris Therapeutics Inc. (ACRS) is also developing its JAK inhibitor, ATI-502, for treating AA. The company announced positive data from a mid-stage study in July.
Apart from these JAK inhibitors, Pfizer has a strong pipeline and anticipates 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. The company’s pipeline candidate, dacomitinib, is under review for first-line treatment of non-small cell lung cancer. A decision is expected by the end of this month.
Pfizer also boasts a strong biosimilars pipeline. Biosimilars in late-stage development include biosimilar versions of Roche’s (RHHBY - Free Report) blockbuster cancer drugs Rituxan and Avastin, and AbbVie’s (ABBV - Free Report) blockbuster rheumatoid arthritis drug, Humira. A biosimilar version of Roche’s Herceptin is under review in the United States and was approved in the EU in July. The company already markets biosimilar version of Merck/J&J’s (JNJ - Free Report) Remicade.
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
Image: Bigstock
Pfizer's Skin Disease Candidates Positive in Mid-Stage Study
Pfizer Inc. (PFE - Free Report) announced positive top-line data from a phase IIa study evaluating its JAK3 inhibitor candidate, PF-06651600, and tyrosine kinase 2/JAK1 inhibitor, PF-06700841, as a treatment for moderate to severe alopecia areata (“AA”).
Both the candidates met the primary endpoint of improving hair regrowth on the scalp compared to baseline over 24 weeks of treatment. Data from the study was presented at the European Academy of Dermatology and Venereology Congress, which was held in France.
The FDA granted Breakthrough Therapy designation to PF-06651600 based on these data earlier this month.
Pfizer’s stock has outperformed the industry this year so far. Pfizer’s shares have risen 18.6% compared with the industry’s increase of 6%.
Alopecia areata is an autoimmune dermatologic condition, which results in patchy non-scarring hair loss, usually affecting the scalp. There is no FDA approved drug presently available to treat this condition, which can lead to high levels of depression and anxiety in patients.
Pfizer will advance PF-06651600 in phase III stage based on the data. The company is also developing PF-06651600 for rheumatoid arthritis, Crohn’s disease (“CD”) and ulcerative colitis (“UC”), and PF-06700841 for psoriasis, CD and UC.
Aclaris Therapeutics Inc. (ACRS) is also developing its JAK inhibitor, ATI-502, for treating AA. The company announced positive data from a mid-stage study in July.
Apart from these JAK inhibitors, Pfizer has a strong pipeline and anticipates 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. The company’s pipeline candidate, dacomitinib, is under review for first-line treatment of non-small cell lung cancer. A decision is expected by the end of this month.
Pfizer also boasts a strong biosimilars pipeline. Biosimilars in late-stage development include biosimilar versions of Roche’s (RHHBY - Free Report) blockbuster cancer drugs Rituxan and Avastin, and AbbVie’s (ABBV - Free Report) blockbuster rheumatoid arthritis drug, Humira. A biosimilar version of Roche’s Herceptin is under review in the United States and was approved in the EU in July. The company already markets biosimilar version of Merck/J&J’s (JNJ - Free Report) Remicade.
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Best Electric Car Stock? You'll Never Guess It
Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!
Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.
See Zacks Best EV Stock Free >>